Daniel Wendling
Expertise in
29
conditions

Daniel Wendling

CHU Gabriel Montpied
Clermont-ferrand, FR 
Expertise in
29
conditions
CHU Gabriel Montpied
Clermont-ferrand, FR 

Overview

Daniel Wendling practices practicing medicine in Clermont-ferrand, France.

Mr. Wendling is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Arthritis, Ankylosing Spondylitis, Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, and Osteotomy.

He is actively involved in clinical research, co-authoring 402 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

CHU Gabriel Montpied
Clermont-ferrand, 63000, France
Other Locations
CHU de Reims
Reims, 51092, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prediction of Adalimumab Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive Spondyloarthritis: Pilot Study
Prediction of Adalimumab Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive Spondyloarthritis: Pilot Study
Enrollment Status: Completed
Publish Date: May 27, 2026
Intervention Type: Drug
Study Phase: Not Applicable
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Enrollment Status: Completed
Publish Date: May 19, 2026
Intervention Type: Drug
Study Drugs: NSAIDs, anti-TNF
Study Phase: Phase 3
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Phase: Phase 4
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug, Biological
Study Drugs: Secukinumab, TNF blocker, Blood specimen
Study Phase: Phase 4
Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)
Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)
Enrollment Status: Withdrawn
Publish Date: May 03, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Not Applicable
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Enrollment Status: Completed
Publish Date: December 04, 2020
Intervention Type: Drug
Study Phase: Phase 3
Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis and Assessment of Their Relations With the Risk of Cardiovascular Disease
Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis and Assessment of Their Relations With the Risk of Cardiovascular Disease
Enrollment Status: Completed
Publish Date: February 12, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

402 Total Publications

Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.
Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.
Journal: EULAR rheumatology open
Published: June 29, 2026

Frequently Asked Questions about Daniel Wendling

Is Daniel Wendling a top-rated expert for Arthritis?

MediFind is an objective health platform that identifies experts based on real-world data. Daniel Wendling is classified as an Elite expert for Arthritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Daniel Wendling participate in research or clinical trials?

Yes. Daniel Wendling has published 402 articles and abstracts on conditions like Arthritis. You can view a list of Daniel Wendling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wendling's expertise for a condition
ConditionClose
View All 10 Elite Conditions
View All 17 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile